Amneal Pharmaceuticals, Inc. (AMRX)
NASDAQ: AMRX · Real-Time Price · USD
13.31
-0.46 (-3.34%)
At close: Mar 3, 2026, 4:00 PM EST
13.24
-0.07 (-0.53%)
After-hours: Mar 3, 2026, 6:42 PM EST
Amneal Pharmaceuticals Revenue
In the year 2025, Amneal Pharmaceuticals had annual revenue of $3.02B with 8.05% growth. Amneal Pharmaceuticals had revenue of $814.32M in the quarter ending December 31, 2025, with 11.47% growth.
Revenue (ttm)
$3.02B
Revenue Growth
+8.05%
P/S Ratio
1.39
Revenue / Employee
$363,706
Employees
8,300
Market Cap
4.19B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.02B | 224.80M | 8.05% |
| Dec 31, 2024 | 2.79B | 400.35M | 16.73% |
| Dec 31, 2023 | 2.39B | 181.30M | 8.20% |
| Dec 31, 2022 | 2.21B | 118.64M | 5.67% |
| Dec 31, 2021 | 2.09B | 101.15M | 5.08% |
| Dec 31, 2020 | 1.99B | 366.15M | 22.51% |
| Dec 31, 2019 | 1.63B | -36.62M | -2.20% |
| Dec 31, 2018 | 1.66B | 629.34M | 60.88% |
| Dec 31, 2017 | 1.03B | 15.43M | 1.52% |
| Dec 31, 2016 | 1.02B | 151.95M | 17.54% |
| Dec 31, 2015 | 866.28M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bausch Health Companies | 10.27B |
| Hims & Hers Health | 2.35B |
| Lantheus Holdings | 1.54B |
| Alkermes | 1.48B |
| Phibro Animal Health | 1.46B |
| Prestige Consumer Healthcare | 1.10B |
| ANI Pharmaceuticals | 883.37M |
| BioCryst Pharmaceuticals | 874.84M |
AMRX News
- 4 days ago - Amneal Pharmaceuticals, Inc. (AMRX) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 4 days ago - Amneal Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 4 weeks ago - Amneal Pharmaceuticals Added to S&P SmallCap 600® Index - GlobeNewsWire
- 5 weeks ago - TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600 - PRNewsWire
- 5 weeks ago - Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026 - GlobeNewsWire
- 7 weeks ago - Amneal Pharmaceuticals, Inc. (AMRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 7 weeks ago - KeifeRx Announces Research Collaboration and Option Agreement with Amneal Pharmaceuticals to Advance KFRX06, a Brain-Penetrant LRRK2 Program for Parkinson's Disease - Business Wire
- 2 months ago - Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA® - GlobeNewsWire